Department of Life Science, Ewha Womans University, Seoul, 03760, South Korea.
The Research Center for Cellular Homeostasis, Ewha Womans University, Seoul, 03760, South Korea.
Nat Commun. 2020 Aug 28;11(1):4343. doi: 10.1038/s41467-020-18208-y.
Osteoarthritis (OA), primarily characterized by articular cartilage destruction, is the most common form of age-related degenerative whole-joint disease. No disease-modifying treatments for OA are currently available. Although OA is primarily characterized by cartilage destruction, our understanding of the processes controlling OA progression is poor. Here, we report the association of OA with increased levels of osteoclast-associated receptor (OSCAR), an immunoglobulin-like collagen-recognition receptor. In mice, OSCAR deletion abrogates OA manifestations, such as articular cartilage destruction, subchondral bone sclerosis, and hyaline cartilage loss. These effects are a result of decreased chondrocyte apoptosis, which is caused by the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in induced OA. Treatments with human OSCAR-Fc fusion protein attenuates OA pathogenesis caused by experimental OA. Thus, this work highlights the function of OSCAR as a catabolic regulator of OA pathogenesis, indicating that OSCAR blockade is a potential therapy for OA.
骨关节炎(OA)主要表现为关节软骨破坏,是最常见的与年龄相关的全关节退行性疾病。目前尚无针对 OA 的疾病修正治疗方法。虽然 OA 主要表现为软骨破坏,但我们对控制 OA 进展的过程知之甚少。在这里,我们报告 OA 与破骨细胞相关受体(OSCAR)水平升高有关,OSCAR 是一种免疫球蛋白样胶原识别受体。在小鼠中,OSCAR 缺失消除了 OA 的表现,如关节软骨破坏、软骨下骨硬化和透明软骨丧失。这些效应是由诱导性 OA 中肿瘤坏死因子相关凋亡诱导配体(TRAIL)引起的软骨细胞凋亡减少所致。用人类 OSCAR-Fc 融合蛋白治疗可减轻实验性 OA 引起的 OA 发病机制。因此,这项工作强调了 OSCAR 作为 OA 发病机制的分解代谢调节剂的功能,表明 OSCAR 阻断是 OA 的一种潜在治疗方法。